cepia

Clinical Epidemiology and Ageing

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

Ettou S, Audureau E, Humbrecht C, Benet B, Jammes H, Clozel T, Bardet V, Lacombe C, Dreyfus F, Mayeux P, Solary E, Fontenay M Leukemia. 2012;26(10):2297-9.
MeSH terms: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CpG Islands; DNA Methylation; fas Receptor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Proportional Hazards Models; Risk
DOI: 10.1038/leu.2012.152
PubMed Google Scholar